CA-XSOLLA
18.7.2024 14:01:34 CEST | Business Wire | Press release
Xsolla, a global video game commerce company, announces the launch of its Mobile Software Development Kit (SDK). Whether you want to expand your payment options, go direct-to-consumer/out-of-store, or simply improve your game’s revenue potential, Xsolla Mobile SDK is the gateway to efficiently and effectively achieve these goals. This release introduces a pivotal solution for the DMA Age, empowering developers worldwide to seamlessly integrate their games on Android and iOS platforms with a global payment solution and web shop. Such integration significantly broadens the potential for mobile game monetization worldwide and unlocks new distribution channels. Game developers like Gaijin Network LTD (Crossout), Artstorm (Modern Warships), LINGCHAI (HONG KONG) LIMITED (Fantasy Tales: Sword and Magic), and ULTRAHORSE (SquadBlast) already use Xsolla SDK to monetize their games.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240718044203/en/
(Graphic: Xsolla)
The launch of the Xsolla Mobile SDK aligns with recent legislative changes worldwide, including in the European Union, particularly the Digital Markets Act (DMA), and confirmed roll-out in Japan and the UK in 2025. This shift represents a critical development in the digital marketplace, providing developers with new monetization avenues to help drive more profits by going beyond traditional app store limitations.
Xsolla’s Mobile SDK Enables Out-of-Store Transactions
Xsolla's Mobile SDK streamlines the process for developers seeking distribution solutions outside the Google Play and App Store. The SDK enables Pay Station to be the primary option for accepting payments for out-of-store transactions. Android developers can integrate it into a self-distributed APK, distributed with channeling partners supporting alternative billing methods. It is also tailored for Web Distribution and App Marketplaces for iOS notarized Apps. Moreover, it is compatible with various game engines, from Unity to Native, making it a versatile and valuable tool for developers looking to enhance their in-game payment experience. Xsolla Mobile SDK complements a Web Shop to enhance out-of-store distribution strategies.
Xsolla’s Mobile SDK Enhances In-Store Transactions with Compliance under DMA
The SDK's features include seamless integration into games already supported by the Google Play Billing Library or Apple StoreKit integrations. Xsolla's Mobile SDK provides additional functionality or replaces billing options tailored to meet Google Play (UCB) and Apple's requirements under the Digital Markets Act (DMA). With Xsolla’s Mobile SDK, games can accept payments with 700+ local payment methods in 200+ territories.
As new regulations emerge, this SDK ensures a smooth expansion to new billing models while maintaining compliance with platform requirements powered by Xsolla Pay Station in other regions.
"With the introduction of our Mobile SDK, Xsolla reaffirms its commitment to supporting mobile game developers through the evolving digital and regulatory economy," said David Stelzer, President of Xsolla. "We're here to help developers navigate the regulatory and compliance changes easily, providing them with the tools to expand their payment options, reduce commission costs, and ultimately drive greater profitability for their mobile games."
The newly released Xsolla Mobile SDK for Android has been available for developers worldwide since today, with iOS support in early access available for those operating within the European Union.
Developers can access the SDK and detailed integration guides by visiting:
Xsolla's Developer Portal
Xsolla Mobile SDK
About Xsolla
Xsolla is a global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in Montreal, London, Berlin, Beijing, Guangzhou, Seoul, Tokyo, Kuala Lumpur, Raleigh, and cities around the world, Xsolla supports major gaming titles like Valve, Take-Two, KRAFTON, Nexters, NetEase, Playstudios, Playrix, miHoYo, and more.
For additional information and to learn more, please visit: xsolla.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240718044203/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kubota Vision Inc. Signs Supply and Licensing Agreement with Laboratoires KÔL for Stargardt Disease Treatment Candidate Under Compassionate Use4.5.2026 17:16:00 CEST | Press release
Kubota Vision Inc. (“Kubota Vision”), a wholly-owned subsidiary of Kubota Pharmaceutical Holdings Co., Ltd. (Minato-ku, Tokyo, Japan) announced signing of a Supply and Licensing Agreement with Laboratoires KÔL (Clermont-Ferrand, France) for the provision of a Stargardt disease (STGD1) treatment candidate under compassionate use authorization. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260414590785/en/ The purpose of this Agreement is for Kubota Vision and KÔL to collaborate on providing “Emixustat” for treatment of Stargardt Disease (STGD1) through compassionate use authorization in France. Kubota Vision will exclusively manufacture and supply Emixustat final products to KÔL and KÔL will have exclusive rights to distribute Emixustat in France under compassionate use access. Ryo Kubota, Chairman, President, and CEO of Kubota Pharmaceutical Holdings, stated, “We are extremely pleased to enter into this Agreement with Labor
Incentive Market Set to Surpass $80B by 2030s — IMA Launches Tools to Help the Industry Keep Pace4.5.2026 16:28:00 CEST | Press release
With combined business spend on loyalty, employee recognition, and channel incentives projected to exceed $80 billion by the 2030s, the incentive industry is entering a period of rapid scale and strategic pressure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422729016/en/ In response, the Incentive Marketing Association (IMA) launched a new suite of resources designed to help incentive professionals navigate an environment that’s becoming more specialized, fragmented, and central to business performance. “It’s not just more money coming in—it’s more complexity,” said Vince Chiofolo, President of the Incentive & Engagement Solution Providers (IESP). “Buyers are demanding programs that evolve fast, integrate deeply, and feel personal at scale. These new tools were built for that.” IMA’s Suite of Tools Includes: New Industry Report — Inside the Incentive Buyer’s Mind Drawn from insights of 50+ program owners, the report f
Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release
Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th
Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release
Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t
Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom